Videos

John P. Sfakianos, MD, shares the clinical rationale for the phase 2 ENHANCE trial, evaluating the addition of NKG2A inhibition to PD-1/PD-L1 inhibition in NMIBC.

Aleece Fosnight, MSPAS, PA-C, highlights the importance of tailoring contraceptive choice to symptom patterns.

Veda N. Giri, MD, shares key findings from the PROGRESS Registry, which evaluated patient-reported outcomes with prostate cancer genetic testing.

In this episode, ‘Strategic Use of ADT in mCSPC From Selection to Escalation,’ the multidisciplinary panelists explore the following questions: With multiple generations of ADT now available in advanced prostate cancer, including oral and injectable options, how do you determine which patients are appropriate candidates for which formulation of ADT? When selecting ADT as the backbone for doublet therapy in metastatic castration-sensitive prostate cancer (mCSPC), in which patients do you prefer the oral versus the injectable option? Which androgen receptor pathway inhibitor (ARPI) do you initiate first? Please explain your rationale. In mCSPC, how do you decide when to escalate from ADT–ARPI doublet to triplet therapy, and what patient or disease factors most influence that decision? How do you weigh potential benefits against added toxicity and contraindications? How does cumulative toxicity influence your willingness to escalate therapy or modify treatment plans?

Welcome back to another Urology Times Peer Exchange series. In this episode titled, ‘Treatment Selection in Advanced Prostate Cancer’, Drs. Paul Sieber, Alicia Morgans, Neeraj Agarwal, and Chad Ritch discussed the following question: When developing treatment plans for prostate cancer, what factors influence treatment selection?

Discover essential insights for managing metastatic prostate cancer, including the importance of clinical trials and early genetic testing.

Pedro F.S. Freitas, MD, recaps his talk at the 2026 Desai Sethi Urology Institute Urology on the Beach meeting.

Sudha Jayaraman, MD, MSc, FACS, recaps a session from the 2026 Urology on the Beach meeting focused on AI in health care.

Although BCG has been the standard of care for decades and remains the most effective available treatment, outcomes remain suboptimal for many patients.

Lina Posada Calderon, MD, discusses the background and key takeaways from her team’s study examining germline BAP1-associated renal cell carcinoma.

Alam frames PHI and MRI as noninvasive tools that help refine risk before proceeding to biopsy.

Despite improvements, Kalyani Narra, MD, highlights persistent gaps in referral among eligible patients.

John P. Sfakianos, MD, outlines the scientific rationale for combining systemic immunotherapy with BCG in the BCG-naïve NMIBC setting.

Wesley Hauwei Chou, MD, outlined 2 projects evaluating potential biomarkers for treatment response in renal cell carcinoma.

When symptoms appear tied to the menstrual cycle, pharmacologic options can be used as short-term support.

Explore the complexities of treatment protocols for metastatic hormone-sensitive patients, focusing on therapy cessation and re-initiation strategies.

Affordability and Accessibility of Therapies in mCSPC Care

Iman Sadri, MD, CM, discusses a somatic-autonomic nerve grafting technique for patients with persistent erectile dysfunction after radical prostatectomy.

The expert faculty discusses how to approach management for patients who experience NMIBC recurrence after receiving combination BCG and checkpoint inhibitor therapy.

The session emphasized how rapidly evolving AI technologies are addressing long-standing inefficiencies in urologic care.

Walter R. Hsiang, MD, MBA, highlights a study looking at access to care, insurance acceptance, wait times, and costs for stone disease management.

Aleece Fosnight, MSPAS, PA-C, highlights pattern recognition as a cornerstone of diagnosis, encouraging clinicians to closely examine how urinary symptoms fluctuate across the menstrual cycle.

A key finding was that among the qualities applicants highlighted, only “learning and growth” correlated with interview selection.

Maxwell L. Sandberg, MD, highlights a study on survival outcomes between patients who underwent CN-TT via an open, laparoscopic, or robotic approach.

Notable findings highlighted stark differences between this safety-net population and national averages.

Fed Ghali, MD, discusses the phase 2 CONSOLIdaTE-01 trial, assessing the role for consolidative local therapy following disease control on EV/P.

Jennifer Miles-Thomas, MD, URPS, MBA, emphasizes that teleurology and team-based care models offer significant promise

Mark D. Tyson, II, MD, MPH, highlights interim findings from the ADVANCED-2 trial of TARA-002 in BCG-naïve NMIBC.

Discover essential tips for new users on rectal spacers, including collaboration, training, and enhancing patient care in radiation oncology.

Experts discuss evolving treatment strategies for metastatic castration-resistant prostate cancer, emphasizing personalized therapy and innovative options.